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INTRODUCTION
Since the completion of the Human Genome Project, one of 
the biggest challenges in genetic research has been the iden­
ti  fication of inherited genetic variants that alter susceptibility 
to multifactorial and polygenic diseases such as cancer [1]. The 
polygenic model for cancer susceptibility presumes that the 
combined effects of variants in many genes, each conferring a 
small to modest increase in cancer risk, cumulatively account 
for a substantial fraction of this heritable component of risk [2]. 
These genetic variants might function through interactions 
with different behavioral, environmental, or other external risk 
factors.
The weight of evidence indicates that cumulative, excessive 
exposure to estrogen across a woman’s life span contributes 
to and may be a causal factor for breast cancer [3]. Several 
endocrine related risk factors that are associated with an 
increased risk of breast cancer in postmenopausal women 
have been found consistently in many studies [4­7]. The 
mechanisms of carcinogenesis in the breast caused by 
estrogen include two different but complementary pathways. 
In addition to the mitogenic properties of estrogen, the 
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Objective: Estrogen plays a key role in breast cancer development and functionally relevant genetic variants within the estrogen 
metabolic pathway are prime candidates for a possible association with breast cancer risk. We investigated the independent 
and the combined effects of commonly occurring polymorphisms in four genes encoding key proteins of estrogen metabolic 
pathway on their potential contribution to breast cancer risk. 
Methods: We studied 530 breast cancer cases and 270 controls of the same age and ethnicity participating in a case­control 
study of postmenopausal women. Genotyping was conducted for CYP1B1 (rs1056836), COMT (rs4680), GSTP1 (rs1695), and 
MnSOD (rs4880) polymorphisms by polymerase chain reaction based restriction fragment length polymorphism and TaqMan 
allelic discrimination method. Adjusted ORs and 95% CIs were calculated using logistic regression. 
Results:  None of the 4 genetic variants examined contributed to breast cancer risk individually. When the combined effects of 
the risk genotypes were investigated, significant associations were observed among women with two high­risk genotypes in 
CYP1B1 and COMT (OR, 2.0; 95% CI, 1.1 to 3.5) and two high­risk genotypes in COMT and MnSOD (OR, 2.0; 95% CI, 1.0 to 3.8), 
compared to those with low­risk genotypes. 
Conclusion:  Our results suggest that individual susceptibility to breast cancer incidence may be increased by combined effects 
of the high­risk genotypes in CYP1B1, COMT, and MnSOD estrogen metabolic genes.
Keywords: Breast neoplasms, Estrogen metabolism, Combined polymorphisms, Association study
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metabolites of estrogen within the catechol estrogen (CE) 
pathway (semiquinones, quinones) damage DNA via the 
formation of superoxide radicals and depurinating DNA 
adducts [8­10]. Because estrogen metabolites have short 
half­lives and are difficult to measure in vivo, assessing the 
associations of breast cancer risk with functional genetic 
variants that alter metabolite concentrations might be the 
most direct approach possible [11]. 
Candidate genes include CYP1A1 and CYP1B1, which 
encode phase I enzymes that lead to increased levels of 
estrogen metabolites and COMT, UGT1A1, SULT1A1, GSTPs, 
and SODs which are involved in phase II metabolism that 
leads to protective conjugation of estrogen metabolites 
or detoxify reactive oxygen species (ROS) formed in these 
reactions (Fig. 1) [12]. CYP1B1 appears to be the main CYP 
responsible for the extrahepatic 4­hydroxylation [13]. The 
4­hydroxyestrogen (4­CE) to 2­hydroxyestrogen (2­CE) 
concentration ratio has been reported to be 4:1 in a human 
breast cancer extract, thus a greater role in carcinogenesis 
has been suggested for 4­CE [14]. Furthermore, quinones, the 
further oxidized metabolites of 4­CE, may react with purine 
bases of DNA to form depurinating adducts that generates 
highly mutagenic apurinic sites. In contrast, quinones of 2­CE 
produce less harmful, stable DNA adducts [9]. COMT enzyme 
is involved in methylating (and thereby inactivating) CEs. This 
is a quantitatively most active conjugation pathway for CEs, 
although they can also be conjugated by glucuronidation 
and sulfation [15]. Members of the GST family are thought to 
play a role in the conjugation of quinones and GSTP1 is the 
major GST expressed consistently in both normal and tumor 
breast tissue [16]. Finally, SODs catalyze the conversion of 
superoxide anion (O2
­) into hydrogen peroxide (H2O2) and 
molecular oxygen, and thus protect cells from the damage 
induced by free radicals emerging in estrogen metabolism. 
As mitochondria consume over 90% of cell oxygen, mito­
chondrial MnSOD is considered of particular importance for 
cellular defense against oxidative damage [17].
Several genetic polymorphisms within estrogen metabolic 
genes have been shown to have functional effects on the 
catalytic properties of their corresponding enzymes. Altered 
activity of phase I and II enzymes may influence local hormone 
levels and cause variation in the extent of DNA damage [18,19]. 
These person­to­person differences may define subpopu­
lations of women with higher lifetime exposure to hormone 
dependent growth promotion and/or to cellular damage 
from particular estrogen metabolites thus suggesting higher 
breast cancer risk. Therefore, the purpose of our study was 
to evaluate the independent and the combined effects 
of CYP1B1, COMT, GSTP1, and MnSOD genotypes on the 
development of breast cancer. Each of the selected genes 
is being highly expressed in breast tissue and involved in 
distinct estrogen metabolic sub­pathway. 
MATERIALS AND METHODS
1. Study population
Postmenopausal women diagnosed with invasive primary 
breast cancer between January 1, 2006 and December 31, 
2008 at the Institute of Oncology Ljubljana, who were 50­
69 years old at the time of diagnosis and of Caucasian ethnic 
origin were eligible for inclusion in the study. The control 
group consisted of postmenopausal women randomly 
selected from the outpatient clinic records of the Department 
of Obstetrics and Gynecology, University Medical Center 
Ljubljana that were of the same age and ethnicity, and had no 
history of breast cancer. 
2. Data collection
In addition to general information (socioeconomic status, 
weight, height), data on reproductive factors (age at menarche, 
number of pregnancies, age at first delivery, number of deli­
veries, breastfeeding, age at menopause), family history of 
breast or ovarian cancer (first­degree relatives), smoking and 
alcohol consumption were collected by means of a postal 
que  stionnaire. Detailed questions were asked regarding drug 
Fig. 1. A schematic presentation of enzymes 
with known gene polymorphisms involved 
in estrogen biosynthesis and metabolism. 
Modified from [12] with permission from 
Elsevier.Jasmina-Ziva Cerne, et al.
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intake, sex hormones in particular (oral contraceptive [OC] 
use, hormone replacement therapy [HRT] use). A color chart 
displaying all preparations ever marketed in Slovenia was in­
cluded in the questionnaire to aid recall. OC and HRT use for 
less than 1 year was considered no use. Women were assumed 
to be postmenopausal if they had no periods for at least 12 
months before the reference date or had undergone a bila­
teral oophorectomy. 
Estrogen receptor (ER) status was assessed by immunohisto­
chemistry, using monoclonal rabbit ER antibody, Clone SP1 
(Neomarkers, Fremont, CA, USA). Tumors were categorized as 
ER­positive if nuclear staining was observed in at least 10% of 
nuclei.
Informed written consent was obtained from all women 
enrolled in the study. The study protocol was approved by the 
National Medical Ethics Committee of the Republic of Slovenia 
(No. 61/06/07). 
3. Specimen collection and isolation of DNA
In case patients, DNA was extracted from formalin­fixed 
paraffin­embedded (FFPE) normal breast tissues using HP 
PCR Template Preparation Kit (Roche Diagnostics GmbH, 
Mannheim, Germany) following the manufacturer’s protocol. 
The control group women were invited to provide blood 
sample; genomic DNA was extracted from whole blood using 
FlexiGene DNA Kit 250 (Qiagen GmbH, Hilden, Germany) 
following the manufacturer’s protocol. 
4. Genotyping
Genotyping for the polymorphism c. 1294C>G (p. Leu432Val) 
in gene CYP1B1 was done using polymerase chain reaction 
(PCR)­based restriction fragment length polymorphism (RFLP) 
method. Each PCR product was digested with restriction en­
do  nuclease Eco57I (Fermentas International Inc, Burlington, 
Canada) and DNA fragments were separated and visualized 
by electrophoresis on polyacrylamide gels. Genotyping for 
the polymorphisms c. 472G>A (p. Val108/158Met) in gene 
COMT, c. 313A>G (p. Ile105Val) in gene GSTP1 and c. 47T> 
C (p. Val16Ala) in gene MnSOD was performed on 96­well 
plates using the fluorogenic 5`­nuclease assays on Light­
Cycler 480 System (Roche Diagnostics GmbH). Each reaction 
mix contained genomic DNA, LightCycler 480 Probes Master 
(Roche Diagnostics GmbH) and Custom TaqMan SNP Geno­
typing Assay (Applied Biosystems, Werterstadt, Germany). All 
genotyping protocols (PCR reaction conditions, primers and 
probes) will be provided upon request from the correspon­
ding author. Positive control samples (homozygote for wild 
allele, heterozygote, homozygote for variant allele) and the 
negative control sample were included in each batch of sam­
ples. Gels were scored by two different readers; discordant 
samples were repeated. Apart from CYP1B1 1294C>G, all poly­
morphisms had no samples that failed to be genotyped. For 
CYP1B1 1294C>G, 1% of the samples failed. Samples that 
failed to be genotyped were scored as missing. Reliability was 
assessed by random selection of 5% of samples in which all 
genotypes were confirmed by sequencing using ABI PRISM 
7000 sequence detection system (Applied Biosystems). Con­
cordance was 100% for all genotypes.
5. Statistical analyses
We used the independent t­test to compare the values 
of the means between cases and controls. Differences in 
categorical characteristics between cases and controls 
were assessed using chi­square tests. Observed genotype 
frequencies were tested for deviation from Hardy­Weinberg 
equilibrium (HWE) with the chi­square goodness­of­fit test. 
Odds ratios (ORs) for breast cancer risk and the corresponding 
95% confidence intervals (CI) were calculated using logistic 
regression analyses. The homozygous wild­type genotype, 
as determined by the presence of two putatively low­risk 
alleles, served as a reference category, with the heterozygous 
genotype and homozygous variant genotype being collapsed 
into one category. The adjustment was made for age as a 
continuous variable. Additional factors (education level, 
body mass index, age at menarche, age at first full term pre­
gnancy, parity, breastfeeding, OC use, age at menopause, 
HRT use, first degree family history of breast and/or ovarian 
cancer and smoking) are within the causal pathway 
between genetic factors and breast cancer, but could not 
be affecting genotypes and are thus not true confounders. 
Therefore, we report the results without adjustment for these 
factors. A p<0.05 was considered statistically significant. 
To account for multiple testing, we used the Westfall and 
Young [20] permutation method, which takes into account 
the interdependency of the variables tested. Our focus was 
different combinations of two and three risk genotypes, since 
their effect was the main hypothesis of the article. We used 
10,000 simulation runs under the null hypothesis of no effect, 
both to correct each p­value by itself and to calculate the 
probability that the significant results had occurred by chance. 
The statistical analyses were done using SPSS ver. 18.0 (SPSS 
Inc., Chicago, IL, USA) and the R statistical software ver. 2.12 (R 
Development Core Team, Auckland, New Zealand).
RESULTS
Overall response rates were 82.5% (825/1,000) for cases and Estrogen metabolism genotypes and breast cancer
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73.2% (732/1,000) for controls. In the 3­year period (2006­
2008), we enrolled 1,493 postmenopausal women aged 50­
69 years; of the 825 cases and 732 controls completing the 
questionnaire, complete data for all variables considered in 
the multivariate model were available for 78.4% (784/1,000) 
cases and 70.9% (709/1,000) controls. Only 38.1 % of the con­
trol women agreed to provide a blood sample. The num  ber 
of cases included in genotype analyses was therefore pro  por­
tionally decreased by random selection to gain the 2:1 ratio 
in case­control comparisons. The final analysis thus in  cluded 
800 postmenopausal women aged 50­69 years: 530 were 
diag  nosed with primary breast cancer and 270 were healthy 
volunteers (control group). The mean age for cases and con­
trols was 60.45±5.84 and 60.10±5.85 years, re  spectively, and 
did not differ significantly between the groups (p=0.432). 
Selected characteristics of the study subjects are presented 
in Table 1. Briefly, cases had significantly higher BMI at the time 
of diagnosis and were more likely to smoke. Control group 
women had a higher educational level, earlier age at menarche 
and were older at first delivery. Significantly more women in 
the control group were using both, OC and HRT. There was no 
significant difference between the groups in the percentage 
of nulliparity, number of full term pregnancies, percentage of 
women that breastfed, duration of breastfeeding, regimen of 
HRT and percentage of women having any first degree family 
history of breast or ovarian cancer.
There was no deviation from the HWE except for GSTP1 
(p=0.01). The chi­square tests for distribution revealed no 
significant difference between cases and controls in most 
of genotype frequencies except for GSTP1 (p=0.04). When 
adjusted for age, none of the 4 genetic variants studied 
was, by itself, statistically significantly associated with post­
Table 1. Characteristics of study population
Variable Cases (n=530) Controls (n=270) p-value
Education - highest degree obtained   Primary school 30.7   6.3 <0.001
Secondary school 59.2 70.3
University, PhD 10.1 23.4
BMI (kg/m2)* <25  33.6 52.2 <0.001
≥25 - <30   40.7 35.1
≥30   25.7 12.7
Age at menarche (yr) 13.7±1.8 13.5±2.1 0.021
Nulliparity   5.3   3.4 0.089
No. of full-term pregnancies
† 1.8±0.9 1.7±0.9 0.127
Age at first delivery (yr)
† 24.3±4.6 24.9±4.8 0.012
Women that breastfed 86.4 90.3 0.344
Duration of breastfeeding (mo)
‡ 8.1±8.7 7.7±7.4 0.269
OC use 42.1 54.7 0.001
Duration of OC use (yr) <1 57.9 45.3 0.002
≥1 - <5 14.4 22.7
≥5 - <10 12.7 17.1
≥10 15.0 14.9
HRT use   29.6 65.8 <0.001
Duration of HRT use   <1 70.4 34.1 <0.001
≥1 - <5 14.3 33.0
≥5 15.3 33.0
Regimen of HRT
§ Combined, estrogen plus progestin 71.2 67.8 0.487
Estrogen only 28.8 32.2
First degree family history of breast and/or ovarian cancer  18.1 15.5 0.138
Smoking   20.2 15.9 0.041
Values are presented as percent (%) or mean±SD. 
BMI, body mass index; OC, oral contraceptive; HRT, hormone replacement therapy.
*Calculated as weight in kilograms divided by height in meters squared at the age of the diagnosis. 
†Among women who had a full term 
pregnancy. 
‡Among those who ever breastfed. 
§Among those who ever used HRT.Jasmina-Ziva Cerne, et al.
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menopausal breast cancer risk (Table 2). 
Additionally, we examined possible combined effects 
of CYP1B1, COMT, GSTP1, and MnSOD  genotypes on 
breast cancer risk by calculating adjusted ORs for all of the 
combinations of two and three of the risk genotypes (Tables 
3 and 4). The reference group consisted of individuals with 
the putatively most advantageous combinations of the 
genotypes, low­risk genotypes, i.e., the presence of homozy­
gous CC genotype for CYP1B1, GG genotype for COMT, AA 
genotype for GSTP1 and TT genotype for MnSOD.
When combinations of two putative at­risk genotypes were 
examined (Table 3), the concurrent presence of CYP1B1 (CG/
GG) and COMT (GA/AA) high­risk genotypes and COMT (GA/
AA) and MnSOD (TC/CC) high­risk genotypes posed a more 
than 2­fold risk of breast cancer (OR, 2.0; 95% CI, 1.1 to 3.5) 
and (OR, 2.0; 95% CI, 1.0 to 3.8), respectively. In contrast, 
no statistically significant effects were seen for women 
simultaneously carrying the GSTP1 high­risk genotype in 
combination with any of the other three the risk genotypes. 
When three of the putative at­risk genotypes were 
combined (Table 4), women with high­risk genotypes CYP1B1 
(CG/GG), COMT (GA/AA), GSTP1 (AG/GG) and CYP1B1 (CG/
GG), COMT (GA/AA), MnSOD (TC/CC) were at a 2.7­fold (95% 
CI, 1.1 to 6.8) and 12.2­fold (95% CI, 1.4 to 102.3) breast cancer 
risk, respectively, compared to those with low­risk genotypes. 
Similarly, clear combined effects were observed also in the 
other two combinations for the three at­risk genotypes, but 
the outcomes were not significant.
After the combinations of two and three risk genotypes were 
examined (Table 3 and 4), the results were further evaluated 
to account for multiple testing. While none of the single 
p­values remained significant after the correction, the overall 
probability that the 8 observed p­values were below 0.05 due 
Table 2. Genetic variation and risk of postmenopausal breast cancer
Genotype Cases Controls OR (95% CI)* p-value
CYP1B1
CC 157 (30.0) 97 (36.1) 1.0
CG 284 (54.3) 129 (47.9) 1.4 (1.0-1.9) 0.068
GG 82 (15.7) 43 (16.0) 1.2 (0.8-1.8) 0.467
CG/GG 366 (70.0) 172 (63.9) 1.3 (1.0-1.8) 0.087
COMT
GG 123 (23.2) 67 (24.8) 1.0
GA 263 (49.6) 136 (50.4) 1.0 (0.7-1.5) 0.804
AA 144 (27.2) 67 (24.8) 1.2 (0.8-1.8) 0.481
GA/AA 407 (76.8) 203 (75.2) 1.1 (0.8-1.5) 0.642
GSTP1
AA 233 (44.0) 130 (48.1) 1.0
AG 243 (45.8) 101 (37.4) 1.3 (1.0-1.8) 0.066
GG 54 (10.2) 39 (14.4) 0.8 (0.5-1.2) 0.292
AG/GG 297 (56.0) 140 (51.8) 1.2 (0.9-1.6) 0.250
MnSOD
TT 118 (22.3) 65 (24.1) 1.0
TC 269 (50.8) 134 (49.6) 1.1 (0.8-1.6) 0.591
CC 143 (27.0) 71 (26.3) 1.1 (0.7-1.7) 0.622
TC/CC 412 (77.7) 205 (75.9) 1.1 (0.8-1.6) 0.564
Values are presented as number (%) or OR (95%  CI). 
OR, odds radio; CI, confidence interval.
*Adjusted for age as a continuous variable.
Table 3. Combined effects of two genotypes (CYP1B1, COMT, GSTP1, 
and MnSOD) and risk of breast cancer
Genotype Cases/controls OR (95% CI) * p-value
CYP1B1  COMT
CC GG 27/26 1.0
CC GA/AA 130/71 1.8 (1.0-3.2) 0.071
CG/GG GG 94/40 2.3 (1.2-4.4) 0.014
CG/GG GA/AA 272/132 2.0 (1.1-3.5) 0.021
CYP1B1 GSTP1
CC AA 69/43 1.0
CC AG/GG 88/54 1.0 (0.6-1.7) 0.942
CG/GG AA 161/86 1.2 (0.7-1.8) 0.518
CG/GG AG/GG 205/86 1.5 (0.9-2.4) 0.088
CYP1B1 MnSOD
CC TT 33/22 1.0
CC TC/CC 124/75 1.1 (0.6-2.1) 0.733
CG/GG TT 84/43 1.3 (0.7-2.5) 0.413
CG/GG TC/CC 282/129 1.5 (0.8-2.6) 0.197
COMT         GSTP1
GG AA 51/27 1.0
GG AG/GG 72/40 1.0 (0.5-1.8) 0.896
GA/AA AA 182/103 0.9 (0.6-1.6) 0.793
GA/AA AG/GG 225/100 1.2 (0.7-2.0) 0.515
COMT         MnSOD
GG TT 19/19 1.0
GG TC/CC 104/48 2.2 (1.1-4.5) 0.037
GA/AA TT 99/46 2.1 (1.0-4.4) 0.041
GA/AA TC/CC 308/157 2.0 (1.0-3.8) 0.050
GSTP1      MnSOD
AA TT 44/28 1.0
AA TC/CC 189/102 1.2 (0.7-2.0) 0.541
AG/GG TT 74/37 1.3 (0.7-2.4) 0.435
AG/GG TC/CC 223/103 1.4 (0.8-2.4) 0.227
OR, odds ratio; CI, confidence interval.
*Adjusted for age as a continuous variable.Estrogen metabolism genotypes and breast cancer
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to chance only was 0.01 (1%).
We were restricted from evaluating the potential combined 
effects of all the four genotypes because none of the cases 
and only one of the controls carried all of the four putatively 
low­risk genotypes simultaneously. 
When stratified for ER status, 84.0% (n=445) of tumors were 
ER­positive and 16.0% (n=85) of tumors were ER­negative. 
Genetic variants alone or combined effects of two genotypes 
did not affect differently breast cancer risk according to the ER 
status (data not shown).
DISCUSSION
In this case­control study of postmenopausal Caucasian 
women, we investigated associations of functionally relevant 
genetic variants in four genes (CYP1B1, COMT, GSTP1, 
MnSOD) encoding key proteins of the estrogen metabolic 
pathway with breast cancer risk. Additionally, we evaluated 
the potential combined effects of these genotypes on the 
development of breast cancer. 
We focused on polymorphic genes coding for enzymes 
that are relevant for the given exposure, are highly expressed 
in breast tissue, and act sequentially in the same metabolic 
pathway (Fig. 1 ­ genes with polymorphisms included in 
our analysis are underlined). However, none of the 4 genetic 
variants in these genes contributed to breast cancer risk 
individually.
Several association studies in these candidate genes have 
been widely used to search for susceptibility alleles, but 
few definite associations have been established [21]. Such 
inconsistencies in results probably reflect the true variation 
in the underlying association between populations studied 
and the low penetrance of mutations in these multigenic 
pathways [22]. Although the effect of each individual 
single nucleotide polymorphism (SNP) was small and not 
significant, the genetic effect of combinations of functionally 
relevant SNPs may additively or synergistically contribute to 
increased breast cancer risk. Therefore, our a priori hypothesis 
specified that individual susceptibility to breast cancer may 
be increased by the combined effects of the risk genotypes 
in estrogen metabolic genes. This was confirmed by the 
results of our study since the concurrent presence of CYP1B1 
and COMT high­risk genotypes and COMT and MnSOD high­
risk genotypes posed a 2­fold risk of breast cancer. Women 
with the three high­risk genotypes CYP1B1, COMT, GSTP1 
and CYP1B1, COMT, MnSOD were at a 2.7­fold and 12.2­fold 
breast cancer risk, respectively. This is in agreement with the 
only gene­gene interaction study that investigated the same 
gene­gene combinations [23]. They observed only marginally 
increased breast cancer risk with the combination of high­risk 
genotypes in CYP1B1, COMT, and MnSOD genes in women 
with the BMI greater than 24 kg/m
2 (OR, 1.4; 95% CI, 1.0 to 1.9) 
[23]. 
Several SNPs within CYP1B1 have been shown to have 
functional effects on the catalytic properties of the CYP1B1 
enzyme, with the 4­hydroxylase activity of the Val
432 variant 
allele displaying a 3­fold higher activity compared to Leu
432 
Table 4. Combined effects of three genotypes (CYP1B1, COMT, 
GSTP1, and MnSOD) and risk of breast cancer
Genotype Cases/
controls OR (95% CI)* p-value
CYP1B1 COMT  GSTP1
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258/129 2.5 (0.7-9.6) 0.173
GA/AA AG/GG TC/CC 166/77 2.7 (0.7-10.5) 0.143
OR, odds ratio; CI, confidence interval.
*Adjusted for age as a continuous variable.Jasmina-Ziva Cerne, et al.
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[24]. On the other hand, the COMT Met
158 variant allele has 
been hypothesized to produce an enzyme with a 3­ to 4­fold 
reduced functionality compared to the wild­type Val
158 allele 
[25]. For GSTP1 gene, a point mutation results in a single amino 
acid change from isoleucine (Ile) to valine (Val) at codon 105. 
This residue lies in close proximity to the hydrophobic binding 
site for electrophilic substrates, and the Val
105 variant allele 
has been demonstrated to exhibit altered specific activity 
and affinity for electrophilic substrates [26]. A polymorphism 
at codon 16 of mitochondrial targeting sequence of the 
MnSOD gene leads to a substitution from Val to Ala. This 
substitution alters the secondary structure of the protein, 
which affects the localization and transport of the enzyme 
into the mitochondria, where it exerts its antioxidant action 
[27]. Therefore, it was first expected that the Val form was 
likely to be associated with increased risk of cancer. However, 
subsequent studies revealed a controversial picture [28]. If 
MnSOD is inhibited to enter the mitochondrial matrix, as is the 
case with Val form, O2
­ cannot be dismutated to H2O2, which 
causes cellular damage and consequently induces apoptosis. 
Conversely, the Ala form of MnSOD efficiently dismutates O2
­ 
to H2O2, but the latter may react to yield other ROS, mostly 
hydroxyl radicals (·OH), which are highly detrimental to DNA. 
In view of these findings, it is very likely that a combination 
of increased production of 4­CE by Val
432 form of CYP1B1 and 
concurrent decreased 4­CE inactivation by Met
158 form of 
COMT may result in elevated risk of breast cancer. Similarly, 
decreased 4­CE inactivation by Met
158 form of COMT leads to 
the production of O2
­, which are generated through the redox 
cycling between further oxidized metabolites, quinones and 
semiquinones. Therefore, while simultaneously carrying Ala
16 
form of MnSOD, excess production of H2O2 may result in the 
accumulation of DNA adducts and thus predispose to cancer. 
On the other hand, rather unexpectedly, the GSTP1 Val
105 
variant allele did not prove to influence breast cancer risk 
when studied separately or when potential combined effects 
between the two risk genotypes were examined. It has been 
suggested that, depending on the chemical composition of 
the substrate, individuals with a given GSTP1 genotype may 
be at a differential risk for carcinogenesis [29]. Since GSTP1 
is polymorphic with 2 single­nucleotide substitutions in the 
coding region (p. Ile105Val and p. Ala114Val), and both amino 
acid residues lie in close proximity to the substrate­binding 
site, their concurrent determination will provide a clearer 
picture of the catalytic properties of the GSTP1 isozyme [29]. 
Furthermore, as the GST family of enzymes are known to 
have overlapping substrate specificities, another explanation 
for the discrepancy might be that the deficiency of GSTP1 
isozyme was compensated by other isoforms (GSTM1, GSTM3, 
GSTT1) [30]. A simultaneous determination of all relevant 
GST genotypes for a given exposure may therefore be a 
prerequisite for a reliable interpretation of the results.
Additionally, we observed a tendency of increased risk 
together with increased number of the putative high­risk 
genotypes. The ORs were more elevated in the women 
harboring three high­risk genotypes compared to two high­
risk genotypes.
The results of the current study suggest that genetic variants 
without or with main effects, too small to be detected, may 
interact with others and confer an increased breast cancer 
risk. Since none of the single p­value remained significant 
after the correction for multiple testing, we can not point 
on a single combination that we expect to have an effect in 
the population. However, as the overall probability that the 
8 observed p­values were below 0.05 due to chance was 
only 1%, we can claim at least some of the studied genotype 
combinations are associated with the increased risk of breast 
cancer. Gene­gene interactions among estrogen metabolic 
genes have been also investigated in other studies, with some 
studies [30­34], but not all [35­37], reporting associations 
between high­risk genotypes and breast cancer risk. However, 
with the exception of two studies reporting marginally 
significant increased risk of breast cancer associated with 
GSTP1, GSTM1, and GSTT1 risk genotypes and our study 
confirming the results of Kocabas et al. [23] indicating 
increased risk associated with CYP1B1, COMT, and MnSOD 
risk genotypes, no specific gene­gene combination has been 
observed in more than one study. Inconsistencies may be at 
least partly explained by the differences in the populations 
studied and in their exposure to the agents relevant to the 
development of breast cancer. Furthermore, for comparable 
statistical power larger study sizes are needed if investigating 
combined effects between different genotypes. The existing 
reports, including ours, were limited only to the interactions of 
SNPs within a single cancer pathway. Yet, there is also growing 
evidence regarding cross talk between the risk genotypes of 
different cancer pathways, including DNA repair, cell cycle, 
immune system and others [38]. The investigation of such 
gene­gene interactions presents new statistical challenges as 
the number of potential interactions between the SNPs can 
be substantial.
Since the current study was retrospective in design, the data 
was obtained on the basis of the postal questionnaire, and a 
low percentage of control group women agreed to provide a 
blood sample, we cannot rule out a possibility of introducing 
biased study results. The difference in how genetic data was 
collected from cases and controls (i.e., FFPE normal breast 
tissue samples in cases and blood samples in controls) might Estrogen metabolism genotypes and breast cancer
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have raised concerns about introducing bias toward a specific 
allele in any of the assays. However, studies have shown that, 
for most of the genotypes, the use of FFPE tissue samples is 
a valid alternative to peripheral blood, and vice versa [39,40]. 
Kweekel et al. [40] compared 11 genotypes in DNA isolated 
from blood and FFPE colorectal cancer tissue and found 
none of the individual genotypes that showed a discordance 
between FFPE cancer tissue and blood significantly different 
from 0.0%, except for GSTP1 (rs1695) with 95% CI 0.1 to 5.9. 
Another study analyzed 5 genotypes selected from regions 
commonly known to have loss of heterozygosity in breast 
cancer from normal breast tissues adjacent to tumors and 
compared them with blood genotyping [41]. They found 
100% concordance and concluded that the use of adjacent 
normal tissues provides accurate genotyping results with 
high specificity [41]. Therefore, by using FFPE normal (not 
cancerous) breast tissue samples, which are unlikely to 
harbour somatic alterations associated with carcinogenesis, 
this might not have affected our ability to identify germ­line 
genetic variants. We have no logical explanation regarding the 
lack of HWE for the GSTP1 (rs1695) in our study. The women in 
the control group were randomly enrolled from the outpatient 
clinic records of the Department of Obstetrics and Gynecology 
during their routine gynecologic exams. Genotyping was 
done in duplicates, using validated Custom TaqMan SNP 
Genotyping Assay and endpoint fluorescence scatter plots 
positioned the homozygotes for one allele, the heterozygotes 
and the homozygotes for the other allele clearly apart from 
each other. Furthermore, no other genetic variant appear 
next to this polymorphism arguing strongly against mismatch 
probe pairing. Additionally, GSTP1 genotyping reliability was 
assessed by sequencing 5% (n=40) of samples at random, 
and concordance was 100%. Therefore, we believe the lack of 
HWE for the GSTP1 is purely due to chance and, since it only 
affected the size of the groups that were compared, it might 
not have introduced any bias into our results. Given extensive 
data stratification in studying the combined effects of the 
three risk genotypes on breast cancer risk, the likelihood of a 
type I error (a false­positive result) has to be considered. Our 
study population was of medium size and it is possible that 
some interactions were not significant due to insufficient 
power. The strengths of the study include homogenous 
study population and investigation of functionally relevant 
genetic variants in genes, each being highly expressed in 
breast tissue and involved in a distinct estrogen metabolic 
sub­pathway. Although the determination of a priori evidence 
of being functionally important in the disease process is 
quite challenging, selecting SNPs based on their functions 
clearly reduces the false positive report probability [42]. The 
results are consistent with biologically plausible interactions 
and merit further investigation of the combined effects of 
polymorphisms in estrogen metabolic genes on breast cancer 
risk. 
Our focus in this study was to find gene­gene interactions, 
which additively or synergistically contribute to breast cancer 
risk. Although our pool of SNPs was small, we have managed 
to show that the individual susceptibility to breast cancer 
incidence may be increased by combined effects of CYP1B1, 
COMT, GSTP1, and MnSOD high­risk genotypes, especially 
in certain combinations. With the exception of one study 
reporting marginally increased breast cancer risk, we are the 
first to report a large increase in breast cancer risk associated 
with these high­risk genotypes. Replication of our results 
is thus needed before any firm conclusion is drawn. These 
findings may provide new important data on the combined 
effects of putative gene­gene interactions in the etiology of 
human breast cancer. We believe that epistasis is likely to be a 
ubiquitous component of the genetic architecture of common 
diseases, such as breast cancer. This information could be 
used in clinical work to identify individuals at increased risk of 
breast cancer, and to develop preventive strategies.
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